U.S. FDA Clears IND for Rubedo’s RLS-1496 for AK; Dr. Emma Guttman-Yassky Joins Company’s Clinical Advisory Board
The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1b/2a study of Rubedo Life Sciences’ RLS-1496 in patients with actinic keratosis (AK).